JANX Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.

$17.66  -1.17 (-6.21%)
As of 11/26/2021 13:00:01 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/11/2021
Outstanding shares:  41,611,510
Average volume:  79,622
Market cap:   $783,544,733
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    47103J105
ISIN:        US47103J1051
Sedol:      BMFX8Y7
Valuation   (See tab for details)
PE ratio:   -38.16
PB ratio:   1.93
PS ratio:   387.70
Return on equity:   -5.55%
Net income %:   -1,034.69%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy